On August 1st, biotech firm DURECT Corporation (NASDAQ:DRRX) released its second quarter financial results for this year. In reaction, Rodman & Renshaw analyst …
Following what is “clearly a disappointing setback in a month that to date had proved to be one of positive surprises for the …
On the eve of FDA advisory committee for brodalumab, a new biologic drug being developed for psoriasis, analyst Raghuram Selvaraju of Rodman & …
MLV analyst Raghuram Selvaraju came out with a research report today on Neuralstem, Inc. (NYSE MKT:CUR) in anticipation of several upcoming clinical catalysts for …
This morning, Advaxis Inc. (NASDAQ:ADXS) held a conference call to provided an update on its pipeline programs and laid out a timeline for multiple milestones …
MLV analyst Raghuram Selvaraju was out pounding the table on Advaxis, Inc. (NASDAQ:ADXS) Friday, reiterating a Buy rating on the stock with a price target of …
In a research report released Wednesday, MLV analyst Raghuram Selvaraju reiterated a Buy rating on Cytosorbents Corp (NASDAQ:CTSO) with a $28 price target, which …
In a research report issued today, MLV analyst Raghuram Selvaraju reiterated a Buy rating on Omeros Corporation (NASDAQ:OMER) with a price target of $38, after the company …
MLV analyst Raghuram Selvaraju came out today with an extremely bullish call on Cytosorbents Corp (NASDAQ:CTSO), initiating a Buy rating and a $30 price target, …
